Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 2/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.45 |
| ▸ | MTOR | P42345 | 2/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.45 |
| ▸ | BRAF | P15056 | 9/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | RIPK2 | O43353 | 6/20 | 0.41 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.41 |
| ▸ | PLK4 | O00444 | 1/20 | 0.41 |
| ▸ | PIR | O00625 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.41 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.41 |
| ▸ | STK16 | O75716 | 1/20 | 0.41 |
| ▸ | OXSR1 | O95747 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14716326 | 0.93 | BRAF (0.48) | HDAC3HDAC2PIK3CBMTORPIK3CG | |
| SCHEMBL14716024 | 0.91 | BRAF (0.48) | PIK3CBMTORPIK3CGPIK3CDBRAF | |
| SCHEMBL17046496 | 0.88 | RIPK2 (0.43) | HDAC3BRAFRIPK2BMPR1BPLK4 | |
| SCHEMBL16505560 | 0.88 | BRAF (0.49) | HDAC3HDAC2PIK3CBMTORPIK3CG | |
| SCHEMBL14716344 | 0.88 | CYP2C19 (0.52) | HDAC3HDAC2BRAFCYP2C9CYP2C19 | |
| SCHEMBL14716241 | 0.86 | BRAF (0.47) | BRAFRIPK2BMPR1BPLK4PIR | |
| SCHEMBL14716150 | 0.85 | BRAF (0.43) | BRAFRIPK2BMPR1BPLK4PIR | |
| SCHEMBL14809264 | 0.84 | BRAF (0.47) | HDAC3HDAC2PIK3CBMTORPIK3CG | |
| SCHEMBL14716233 | 0.84 | BRAF (0.43) | BRAFRIPK2BMPR1BPLK4PIR | |
| SCHEMBL14716161 | 0.84 | BRAF (0.45) | BRAFRIPK2BMPR1BPLK4PIR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200390763-A1 | BENZENESULFONAMIDE DERIVATIVES OF QUINOXALINE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN METHODS FOR TREATING CANCER | NEUPHARMA, INC. | 2020-12-17 | — | — | US | claimed |
| EP-2747767-B1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA INC (US) | 2019-02-20 | — | — | EP | claimed |
| US-9295671-B2 | Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer | NEUPHARMA, INC. (US) | 2016-03-29 | — | — | US | claimed |
| US-20130053384-A1 | Certain Chemical Entities, Compositions, and Methods | NEUPHARMA, INC. (US) | 2013-02-28 | — | — | US | claimed |
| US-20200390763-A1 | BENZENESULFONAMIDE DERIVATIVES OF QUINOXALINE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN METHODS FOR TREATING CANCER | NEUPHARMA, INC. | 2020-12-17 | — | — | US | disclosed |
| US-10561652-B2 | Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer | NEUPHARMA, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| EP-2747767-B1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA INC (US) | 2019-02-20 | — | — | EP | disclosed |
| US-10137125-B2 | Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer | NEUPHARMA, INC. (US) | 2018-11-27 | — | — | US | disclosed |
| US-20170340630-A1 | BENZENESULFONAMIDE DERIVATIVES OF QUINOXALINE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN METHODS FOR TREATING CANCER | NEUPHARMA, INC. | 2017-11-30 | — | — | US | disclosed |
| US-9572808-B2 | Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer | NEUPHARMA, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20160303118-A1 | BENZENESULFONAMIDE DERIVATIVES OF QUINOXALINE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN METHODS FOR TREATING CANCER | NEUPHARMA, INC. | 2016-10-20 | — | — | US | disclosed |
| US-9295671-B2 | Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer | NEUPHARMA, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-9295671-B2 | Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer | NEUPHARMA, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-9295671-B2 | Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer | NEUPHARMA, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20130053384-A1 | Certain Chemical Entities, Compositions, and Methods | NEUPHARMA, INC. (US) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200390763-A1 | BENZENESULFONAMIDE DERIVATIVES OF QUINOXALINE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN METHODS FOR TREATING CANCER | PDXK, BRAF, CHEK1 | HDAC3 1698/4885HDAC2 2108/4885PIK3CB 145/4885 |
| US-10561652-B2 | Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer | PDXK, BRAF, CHEK1 | HDAC3 1698/4885HDAC2 2108/4885PIK3CB 145/4885 |
| US-20160303118-A1 | BENZENESULFONAMIDE DERIVATIVES OF QUINOXALINE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN METHODS FOR TREATING CANCER | PDXK, BRAF, CHEK1 | HDAC3 1698/4885HDAC2 2108/4885PIK3CB 145/4885 |
| US-20170340630-A1 | BENZENESULFONAMIDE DERIVATIVES OF QUINOXALINE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN METHODS FOR TREATING CANCER | PDXK, BRAF, CHEK1 | HDAC3 1698/4885HDAC2 2108/4885PIK3CB 145/4885 |
| US-10137125-B2 | Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer | PDXK, CHEK1, CHEK2 | HDAC3 1933/4885HDAC2 2578/4885PIK3CB 164/4885 |
| US-20130053384-A1 | Certain Chemical Entities, Compositions, and Methods | BRAF, PIK3CA, PLK1 | HDAC3 1072/4885HDAC2 986/4885PIK3CB 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.